Provider FAQ
Straight answers to what providers actually ask.
These are the real questions we get before a practice runs its first study. If yours is not here, ask us directly — we would rather answer it now than have you discover it in month three.
Section 01
Getting started
What research actually involves, and whether your practice is ready.
You are probably thinking of grant-based academic research, which is a common and understandable misconception. Clinical trial research tests the safety, efficacy, or effectiveness of medical interventions such as drugs and devices, following a protocol, usually toward regulatory approval or improved patient care. Documentation requirements resemble what you already do for a typical patient encounter.
Yes. Training programs such as Good Clinical Practice certification, combined with collaboration with our team, close the gap quickly. Every study also carries protocol-specific training that we deliver and document. Most investigators we work with had no formal research background before their first study.
Many trial activities can be delegated to trained staff, exactly as in your normal practice. We can train your nurse, embed one of our coordinators in your office, or provide clinical staff for study encounters. Our remote nursing team also absorbs between-visit follow-up, so a protocol with a long follow-up window does not consume your staff for a year.
Realistically, you already have what you need. Most sponsors prefer to supply study-specific items in order to guarantee consistency across sites. Anything you do not have and the sponsor does not provide, we provide at no cost to you.
Large institutions carry high overhead, layered bureaucracy, and startup delays. Smaller site networks offer lower costs and faster startup, which appeals to sponsors managing development programs that run from hundreds of millions of dollars into the billions. Community sites, particularly in suburban and rural areas, also tend to improve recruitment and population diversity — a direct answer to the more than 80% of trials that fail to meet enrollment timelines under urban-centric site selection.
Section 02
Patient safety and ethics
The oversight structure that governs everything we do.
Trials operate under strict ethical oversight through institutional review boards and a phased structure, from Phase I through Phase IV, specifically designed to prioritize safety by starting with small, closely controlled groups. For practices new to research we typically seek out and recommend Phase III and IV studies or studies of non-investigational products until you are ready to consider earlier phases.
Regulations mandate clear, comprehensive informed consent documents, and we ensure participants also receive a verbal explanation tailored to their level of comprehension. Consent is a process rather than a signature, and it continues throughout participation.
The investigator retains responsibility for the safety of participants under their care and for the conduct of the trial at their site. Our role is to make that oversight practical: defined escalation pathways for adverse events, documented delegation of every trial-related activity, trained and credentialed staff, and records that are accessible for monitor review and inspection.
Most studies offer compensation to cover the reasonable costs of participation, such as travel and time. Compensation amounts are reviewed and approved by the IRB to ensure they are not coercive.
Section 03
Operations and payment
Paperwork, billing, and how money actually moves.
Most providers prefer that Premier Bioservices handle the more tedious paperwork, and that is exactly our service to you. Regulatory submissions, essential documents, delegation logs, training records, and deviation documentation are ours. What remains with you looks much like ordinary clinical documentation.
Pleasantly, none of the usual way. There are no CMS-1500 claim forms or clearinghouses, and no prior authorizations or denials. We work with the sponsor to establish a payment schedule as part of the budget, manage the billing on your behalf, and pay you directly on a set schedule — usually per patient encounter.
By reading the protocol closely and negotiating against what it actually requires rather than what the initial budget offers. Our negotiations generally yield around 25% higher reimbursement, largely by identifying protocol-mandated work that the original budget left unfunded.
We agree recruitment and marketing strategy with the sponsor before activation, so there is a plan in place on day one rather than a scramble in month three. We also pre-screen against the patient population you already treat before recommending a study, which is the single best predictor of whether you will enroll.
We would rather not brag, but if you have heard of them, chances are we have worked with them recently. We communicate frequently with manufacturers and clinical research organizations to keep a read on the industry and to position for upcoming opportunities.
It is a real and substantial industry. The US clinical trials market was valued at approximately $25.8 billion in 2023, and the global site management organization market alone was around $6.2 billion in 2023, projected to reach roughly $9.5 billion by 2030. Our team has been conducting clinical trial research for over twenty years. We are glad to talk through references, structure, and economics in detail before you commit to anything.
Section 04
Remote monitoring and decentralized studies
How follow-up works when it is not happening in your office.
Yes, and explicitly. In September 2024 the FDA finalized Conducting Clinical Trials With Decentralized Elements, which supersedes the 2023 draft guidance. It expressly contemplates telehealth visits with trial personnel, in-home visits by remote trial personnel, visits with local healthcare providers, and remote data collection through digital health technologies. Regulatory requirements are the same whether or not a trial includes decentralized elements.
Licensed clinical nurses on our team, working as trial personnel under the investigator's oversight and on the delegation log. Where a protocol calls for activities that a local healthcare provider can perform within their ordinary scope of practice, such as vitals or a blood draw, those can be delegated locally — and per FDA guidance, local HCPs performing only such activities generally need not appear on Form FDA 1572.
It changes what has to be controlled. FDA notes that remote assessments may differ from on-site assessments and that assessments performed by local healthcare providers can be more variable. The mitigations are training, standardization, clear delegation, and keeping protocol-specific or investigational-product-specific assessments with qualified trial personnel. Handled that way, remote follow-up typically improves data completeness, because missed visits are the larger threat to a dataset than measurement variation.
It can, substantially. On-site monitoring alone accounts for as much as 30% of total clinical trial cost, so shifting appropriate verification to remote review is one of the larger cost levers available. The bigger effect is usually retention: a participant who does not have to travel for every assessment is far more likely to complete the study.
Wound care is the clearest case for it. AI-assisted smartphone wound imaging can be captured by the participant or a visiting nurse and reviewed remotely, so a stalling or deteriorating wound is escalated within days rather than at the next monthly visit. Given that US diabetic foot ulcer trials average 1.51 patients per site per month and that reduced travel burden is a documented driver of faster enrollment, remote assessment is not a convenience in this indication — it is the mechanism.
Yes, and they are handled deliberately. Remote visits must comply with the telehealth practice laws of the state in which the participant is located, which can include specific consent requirements, minimum permitted modalities, patient identification rules, and medical records obligations. We confirm licensure and applicable state requirements as part of study startup rather than after the first visit is scheduled.
Still deciding
Two things worth reading next.
Ask us directly
If your question is not here, it is still a fair question.
We would rather answer it now than have you discover the answer in month three of a study.